4 Of The Best Income Stocks Around: GlaxoSmithKline plc, Standard Life Plc, SSE PLC And Centrica plc

GlaxoSmithKline plc (LON: GSK), Standard Life Plc (LON: SL), SSE PLC (LON: SSE) and Centrica PLC (LON:CNA) are four of the best dividend plays around.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Standard Life (LSE: SL) has transformed itself into an income champion over the past five years. The company’s shift to a fee-based business model has led to a tripling of cash flow generated from operations since 2010. Assets under management have risen by 50% over the same period. 

This growth has helped support the company’s dividend payout growth. Since 2011 Standard’s dividend payout has increased at a steady rate of 7% per annum. Since 2010 Standard Life has returned 147p per share to investors, including the recent special dividend and over five years the shares have produced a total return of 180%. Based on the estimated growth of the UK pension market, the next five years could see a similar performance. 

Standard Life trades at a forward P/E of 16.8 and supports a yield of 4.6%. Earnings per share are predicted to grow by 48% this year. 

Dividend concerns 

GlaxoSmithKline’s (LSE: GSK) shares have sunk to a four-year low on fears about the sustainability of the company’s dividend payout. However, to a certain extent, these concerns are unfounded.

Management has stated that the company’s dividend of 80p per share is safe for the next three years. A special dividend of 20p per share payable during the fourth quarter will take the total payout for 2015 to 100p per share, a yield of 7.9% based on Glaxo’s current share price. 

Glaxo currently trades at a forward P/E of 16.9 and supports a yield of 7.2%. Earnings per share are predicted to shrink by 21% this year. 

Slow and steady 

Last year, SSE (LSE: SSE) made a commitment to target an increase in the full-year dividend for 2015/16 of at least RPI inflation, with annual increases thereafter of at least RPI inflation also being targeted.

This is hardly the most impressive dividend policy. The RPI measure of inflation has averaged 1% this year, so investors won’t see much in the way of a dividend increase at all. 

Nevertheless, for the conservative dividend investor SSE’s dividend policy is ideal. The payout is covered 1.2 times by earnings per share and due to the nature of SSE’s business, the company has a certain degree of clarity over its revenue streams. As a result, it’s unlikely management will suddenly take an axe to the dividend. 

SSE currently trades at a forward P/E of 12.6 and supports a yield of 6.2%. Earnings per share are predicted to shrink by 10% this year.

Changing business model 

Centrica (LSE: CNA) has already cut its dividend payout once this year. However, according to City projections the new, lower payout is now covered one-and-a-half times by earnings per share, leaving plenty of room for manoeuvre. 

What’s more, management’s recent decision to scale back Centrica’s upstream business is a great move for the company. Oil & gas production is a notoriously volatile and capital intensive business. Focusing on the more predictable customer-facing side of the business should put Centrica back on the path to long-term sustainable growth.

Also, Centrica’s focus on the more predictable customer side of the business should help the company maintain and increase its dividend over time.  

Centrica currently trades at a forward P/E of 12.5 and supports a yield of 5.4%. Earnings per share are predicted to shrink by 7% this year.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended Centrica and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Stack of one pound coins falling over
Investing Articles

Want to build a high-yield share portfolio for dividend income? 3 things to watch

A high yield can be very tempting -- and sometimes it can turn out to be very lucrative too. But…

Read more »

The Troat Inn on River Cherwell in Oxford. England
Investing Articles

Down 10% already this year, is there any hope for the Diageo share price?

Diageo shares have not had a positive start to 2026, unlike the wider FTSE 100 index. Our writer is hanging…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Up 28% in under a month, is Nvidia stock taking off again?

Close to an all-time high, our writer still sees many things to like about Nvidia stock. But is the current…

Read more »

Queen Street, one of Cardiff's main shopping streets, busy with Saturday shoppers.
Investing Articles

Is this news a minor development for Greggs shares – or potentially a major one?

Could stopping some sausage rolls being stolen really make much difference for Greggs shares? Our writer explains why he sees…

Read more »

The Mall in Westminster, leading to Buckingham Palace
Investing Articles

1 top ETF yielding 4.6% to consider for a £20,000 Stocks and Shares ISA

Our writer highlights an exchange-traded fund that new Stocks and Shares ISA investors could consider to get the passive income…

Read more »

Young woman holding up three fingers
Investing Articles

3 ways to try and build wealth using a Stocks and Shares ISA

An ISA can help someone try and grow their financial resources, in more ways than one. Christopher Ruane explains how…

Read more »

Investing Articles

£15,240 saved in a Cash ISA in 2016 is now worth…

Harvey Jones shows how much money the average Cash ISA would have returned over the last decade, and how stocks…

Read more »

Two gay men are walking through a Victorian shopping arcade
Investing Articles

2 stupidly cheap shares to consider buying now to try and make a million

Harvey Jones picks out two cheap shares from the FTSE 100 that remain astonishingly good value despite their recent strong…

Read more »